Associated Genetic Biomarkers
FRS2 Amplification is present in 1.74% of AACR GENIE cases, with breast carcinoma, non-small cell lung carcinoma, ovarian neoplasm, melanoma, and bile duct carcinoma having the greatest prevalence .
FRS2 Amplification serves as an inclusion eligibility criterion in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains FRS2 Amplification as an inclusion criterion, 1 is phase 1 (1 open).
Trials with FRS2 Amplification in the inclusion eligibility criteria most commonly target hepatocellular carcinoma and malignant solid tumor .
Significance of FRS2 Amplification in Diseases
Malignant Solid Tumor +
FRS2 is mutated in 3.45% of malignant solid tumor patients with FRS2 Amplification present in 3.45% of all malignant solid tumor patients .
FRS2 Amplification is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FRS2 Amplification and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) .
Hepatocellular Carcinoma +
FRS2 Amplification is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FRS2 Amplification and hepatocellular carcinoma as inclusion criteria, 1 is phase 1 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.